Research
Silencing a liver gene may prevent brain damage from rare metabolic disease
The Brief
- A Duke University School of Medicine study reports the first preclinical success of a liver-targeting treatment for glutaric aciduria type I (GA1).
- The approach silences a liver gene as a way to protect the brain from damage caused by GA1, a rare metabolic disease.
- The findings are preclinical, so they have not yet been tested in human patients.
Why it matters
It suggests a new strategy for a rare brain-damaging metabolic disorder, showing that targeting the liver may affect neurological outcomes.
Who’s affected
- researchers and clinicians working on rare metabolic diseases
- families affected by glutaric aciduria type I
- #metabolic disease
- #gene silencing
- #liver
- #neuroscience
- #rare disease
What if the path to treating a rare condition that harms the brain goes through the liver? A new study by Duke University School of Medicine researchers is the first to show preclinical success of a liver-targeting treatment of glutaric aciduria type I (GA1).